Boston Scientific Loses Heart
Boston Scientific (BSX) reported that sales for the first quarter of 2007 were $2.086 billion as compared to $1.620 billion for the first quarter of 2006. EPS came in at $.08. Analysts surveyed by Thomson Financial estimate earnings per share…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Boston Scientific (BSX) reported that sales for the first quarter of 2007 were $2.086 billion as compared to $1.620 billion for the first quarter of 2006. EPS came in at $.08.
Analysts surveyed by Thomson Financial estimate earnings per share of 10 cents on revenue of $2.08 billion.
The company’s drug coated stent business is still in the out-house. Worldwide sales of the drug-eluting coronary stent systems for the first quarter of 2007 were $468 million as compared to $633 million for the first quarter of 2006
Guidance was mediocre. BSX estimates net sales for the second quarter of 2007 of between $2.0 billion and $2.1 billion. In addition, EPS on a GAAP basis should be between $0.04 and $0.09 per share.
The shares dropped more than 2% on the news.
Just another bad quarter.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.